Article
NexImmune sizes up the competition and decides to pause myeloma T-cell therapy plans
Rating:
0.0
Views:
52
Likes:
1
Library:
1
Turns out NexImmune is not resistant to the tough competition in multiple myeloma. | NexImmune has cited tough competition as the reason for pausing enrollment on one of its two clinical candidates, as the company diverts resources into launching a solid tumor therapy into human studies.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value